Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies

OBJECTIVE: Relapse of AML after allogeneic hematopoietic stem cell transplantation (HSCT) has a poor prognosis, and standard of care therapy is lacking. Early (<6 months) relapse is associated with dismal outcome, while the majority of relapses occur early after transplantation. A more precise in...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Greta, Janssen, Jeroen J. W. M., Biemond, Bart J., Zeerleder, Sacha S., Ossenkoppele, Gert J., Visser, Otto, Nur, Erfan, Meijer, Ellen, Hazenberg, Mette D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851577/
https://www.ncbi.nlm.nih.gov/pubmed/31411761
http://dx.doi.org/10.1111/ejh.13315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851577/
https://www.ncbi.nlm.nih.gov/pubmed/31411761
http://dx.doi.org/10.1111/ejh.13315

Ejemplares similares